MoA

Assess mechanism of action, host Response, activity, profiling & efficacy of your antimicrobials.

Assess novelty of antibiotic mechanism of action using a Label-free technology

Identify the target(s) or pathways of a therapeutic candidate

Lead to candidate translation

Proof of concept, PK/PD

Early prediction of therapeutic solution activity

Host response triggered by your therapeutic solutions

Identification of molecular signatures of infection resolution and treatment efficacy

Biofilm solution evaluation in chronic infectious diseases

Mechanism of action – Host response, activity, profiling & efficacy of your antimicrobials

Assess mechanism of action, host response, activity, profiling & efficacy of your antimicrobials to efficiently fuel the translational pipeline of new drugs for the benefit of patients.

New agents displaying innovative chemistry and modes of action are desperately needed worldwide to tackle the public health menace posed by antimicrobial resistance. In the recent years, biological and technological advances have opened the door to a more accurate characterization of antimicrobials.

We propose both bespoke cutting edge and robust state of the art solutions relying on solid practices in traditional microbiology to assess Mechanism of action, Host Response, Activity, Profiling & Efficacy of your antimicrobials to efficiently fuel the translational pipeline of new drugs for the benefit of patients.

1

Assess novelty of antibiotic mechanism of action using a Label-free technology

As an alternative to time consuming and cumbersome current technologies (such as macromolecular screening assays, MMS or various labeled assays), we have developed label free technologies to explore the mechanism of action of your new antibiotics discovered through phenotypic screening.

Combining either metabolomics (Watch here Met-SAMoA video) or holographic optics (Consult our case study HoloMoA here) with artificial intelligence, we rapidly compare the unknown MoA of your antibiotic with those of marketed ones, assessing the novelty of your molecule or giving a solid clue for deeper investigations of its mode of action and potential target(s).

You can discover our OMICS and Bioassays & Microsystems technologies here, and learn more about our In Vitro / In Vivo Models offer there.

2

Identify the targets or pathways of an antimicrobial candidate

Identification of drug targets or pathways involved in the MoA of your antibiotic are explored at an early stage, through our multiomic approach associated to bioinformatics and biostatistics analyses (MultiOMICS-MoA). Resistance are also investigated using classical assays like serial passages. Molecular mechanisms of resistance are unraveled through technologies such as TnSeq, or KO or KI strains of resistance genes.

In addition, we have developed NMR and MS based fingerprinting strategy to rapidly differentiate the mode of action of your antimicrobial from known drugs. We deploy interactomic strategies allowing identification and molecular characterization of cell/cell, cell/protein, protein/protein interactions.

Identify the targets or pathways of an antimicrobial candidate
3

Identification of molecular signatures of infection resolution and treatment efficacy

To limit risk of antimicrobial resistance (AMR) or toxicity in the context of latent/persistent infections, we are able to identify the most relevant molecular signatures to effectively monitor your drug therapy response. We implement an integrated approach combining:

  • ­rationalized targeted and untargeted OMICs technologies,
  • ­and advanced bioinformatic expertise.

This approach allows distinguishing early, late responders to non-responders to your drug candidate.

Read more about our case study ISIT-TB here.
Explore our Biomarkers offer here.

Evaluation of prophylactic/therapeutic vaccines immunogenicity
4

Impact of your antimicrobial solution on host response triggered by infection

We measure the immunological impact (cytokine mobilization, neutralizing antibody production…) of your product on host response throughout the spread of the infection, during its resolution, and in the recovery phase, by cellular and molecular characterization. This immunomonitoring can be carried out, over time, qualitatively and quantitatively, in peripheral blood or tissues.

Thanks to an adaption of usual preclinical models to immunocompetent mice, we can hence evaluate the efficacy of immunomodulators as well as alternative approaches like virulence factor inhibitors or phages.

Impact of your antimicrobial solution on host response triggered by infection
5

Early prediction of therapeutic solution activity

For early prediction of the activity of your novel drug, we implement in vitro or ex vivo assays that include or reconstitute the biological and immunological components involved in the host-pathogen-drug interactions. Complementary to state-of-the art tests including (MICs, MBC, Time-kill, FICI, Cross resistance, FoR,) we may also bring together:

  • actionable readouts for probiotics, vaccines and antimicrobial strategies (Test on clinical samples like infected urine, blood, sputum, biopsy),
  • apply validated organ on chip solution (blood, lung, but also biofilm),
  • develop & implement proprietary integrated single cell.

Here is our Microbiology and molecular engineering technology.

6

Drug activity and efficacy on Biofilms

The presence of biofilms during infections requires new methods of prevention, diagnosis and treatment. We have developed a specific platform dedicated to the study of antibiofilm products. Read more about our Microbiology and molecular engineering technology here.

Complementary to microplate based assays, we deploy a proprietary technology, to produce high quality biofilms that allow reproducible evaluation of your antibiofilm products. Antibiofilm activity of your drug can be measured using state of the art assay.

Alternatively, using a dynamic shear stress model of biofilm, we can measure the activity of your products in a more translatable to in vivo system. In addition, we have an ambitious project aiming at developing a Biofilm-on-chip system. Finally, we can evaluate the in vivo efficacy of your product using biofilm adapted preclinical models (biofilms engraftment or formation-stimulated) on abiotic surfaces (like catheter) or biotic surfaces (skin ulcer, wounds).

Discover our In vitro / in vivo models offer here.

7

Profiling your antimicrobial advanced leads and candidates

In order to help you select the advanced leads to progress towards the in vivo efficacy study, we propose to evaluate your product in vitro on bacteria cultured in alternative media mimicking in vivo conditions. In such media all the survival systems of bacteria are stimulated, making the in vitro evaluation of your drug more translatable to in vivo. Some of these biomimetic systems are coupled with microfluidic chips, to have an even more relevant dynamic environment in which we have earlier access to the interaction between host, pathogen and drug.

To improve the translation rate of your advance candidates to clinical Proof of Concept, we have the capacity to measure the antimicrobial susceptibility pattern of your antimicrobial on collections of relevant clinical strains gathered from our hospital network.

8

Efficacy of your antimicrobial on relevant and customized preclinical models

Upstream to the efficacy evaluation, we propose to study the biodistribution and pharmacokinetics of your product, in order to optimize the therapeutic regimen.

Our bespoke preclinical infectious diseases models are systematically adapted to your product and your questions. Among our preclinical models, we can mention pneumonia, septicemia, UTI, SSTI…For in vivo Proof of Concept, we have developed preclinical imaging solutions to conduct longitudinal efficacy studies of your product. For that, we have gathered a unique collection of bioluminescent-engineered bacteria from the ESKAPE list.

Please see our Preclinical Models & Imaging technology here.

You will find our In Vitro / In Vivo Models offer here.

2

Identify the targets or pathways of an antimicrobial candidate

Identification of drug targets or pathways involved in the MoA of your antibiotic are explored at an early stage, through our multiomic approach associated to bioinformatics and biostatistics analyses (MultiOMICS-MoA). Resistance are also investigated using classical assays like serial passages. Molecular mechanisms of resistance are unraveled through technologies such as TnSeq, or KO or KI strains of resistance genes.

In addition, we have developed NMR and MS based fingerprinting strategy to rapidly differentiate the mode of action of your antimicrobial from known drugs. We deploy interactomic strategies allowing identification and molecular characterization of cell/cell, cell/protein, protein/protein interactions.

Identify the targets or pathways of an antimicrobial candidate
4

Impact of your antimicrobial solution on host response triggered by infection

We measure the immunological impact (cytokine mobilization, neutralizing antibody production…) of your product on host response throughout the spread of the infection, during its resolution, and in the recovery phase, by cellular and molecular characterization. This immunomonitoring can be carried out, over time, qualitatively and quantitatively, in peripheral blood or tissues.

Thanks to an adaption of usual preclinical models to immunocompetent mice, we can hence evaluate the efficacy of immunomodulators as well as alternative approaches like virulence factor inhibitors or phages.

Impact of your antimicrobial solution on host response triggered by infection
6

Drug activity and efficacy on Biofilms

The presence of biofilms during infections requires new methods of prevention, diagnosis and treatment. We have developed a specific platform dedicated to the study of antibiofilm products. Read more about our Microbiology and molecular engineering technology here.

Complementary to microplate based assays, we deploy a proprietary technology, to produce high quality biofilms that allow reproducible evaluation of your antibiofilm products. Antibiofilm activity of your drug can be measured using state of the art assay.

Alternatively, using a dynamic shear stress model of biofilm, we can measure the activity of your products in a more translatable to in vivo system. In addition, we have an ambitious project aiming at developing a Biofilm-on-chip system. Finally, we can evaluate the in vivo efficacy of your product using biofilm adapted preclinical models (biofilms engraftment or formation-stimulated) on abiotic surfaces (like catheter) or biotic surfaces (skin ulcer, wounds).

Discover our In vitro / in vivo models offer here.

8

Efficacy of your antimicrobial on relevant and customized preclinical models

Upstream to the efficacy evaluation, we propose to study the biodistribution and pharmacokinetics of your product, in order to optimize the therapeutic regimen.

Our bespoke preclinical infectious diseases models are systematically adapted to your product and your questions. Among our preclinical models, we can mention pneumonia, septicemia, UTI, SSTI…For in vivo Proof of Concept, we have developed preclinical imaging solutions to conduct longitudinal efficacy studies of your product. For that, we have gathered a unique collection of bioluminescent-engineered bacteria from the ESKAPE list.

Please see our Preclinical Models & Imaging technology here.

You will find our In Vitro / In Vivo Models offer here.